Physician profile
Cortnee N Lingerfelt
NPI 1649622374
$1,105.57
in general payments reported to CMS, 2019-2025
14 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $221 · 2023: $392 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $278.34 | 2022-2025 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $171.53 | 2023-2025 | Keytruda, Lynparza |
| Myriad Genetic Laboratories, INC. | $154.69 | 2023 | Myrisk |
| Eisai INC. | $131.89 | 2022-2025 | |
| Genmab U.S., INC. | $108.22 | 2023-2025 | Tivdak |
| Abbvie INC. | $50.19 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $41.44 | 2023-2025 | Lynparza |
| Caris Mpi, INC. | $35.71 | 2025 | Mi Cancer Seek |
| Clovis Oncology, INC. | $31.37 | 2022 | |
| Daiichi Sankyo INC. | $28.77 | 2025 | Enhertu |
| Lilly USA, LLC | $20.15 | 2023 | Retevmo |
| Seagen INC. | $19.39 | 2023 | Tukysa |
| Astellas Pharma US INC | $18.89 | 2023 | Veozah |
| Immunogen, INC. | $14.99 | 2023 | Elahere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cortnee Lingerfelt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.